Home › Therapeutic areas › Oncology › Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (5 companies)

Companies with an active program in Acute Lymphoblastic Leukemia.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ARTV Artiva Biotherapeutics Oncology 1 Phase 1 $191M 6
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 3 Approved $290M 12
FBIO Fortress Biotech DermatologyHematology+4 Rare 1 Approved $61.4M 16
KURA Kura Oncology MetabolicOncology 1 Approved $688M 13
SLS SELLAS Life Sciences Group Oncology 1 Phase 3 $3.90B 9